Category: Cancer Immunocology Therapies

  • Boehringer Ingelheim Acquires Abexxa to Expands its Immuno-oncology Research

    Shots: The acquisition includes upfront, milestones, and other consideration payments. Abexxa will continue to operate in the Arlington The acquisition will allow Boehringer to access Abexxa’s expertise and capabilities in targeting cancer-specific proteins by using its technology to develop cancer immunotherapies and Abs for solid cancers The acquisition also bolsters Boehringer’s commitment to identifying the […]